See analyst estimates and all valuation multiples for Biopharmaceuticals
Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
$684B | 13.4x | 34.1x | |
$393B | 6.8x | 15.1x | |
$383B | 4.3x | 11.8x | |
$315B | 6.8x | 13.8x | |
$274B | 3.7x | 9.4x | |
$244B | 4.5x | 11.0x | |
$242B | 4.2x | 12.2x | |
$217B | 3.4x | 7.9x | |
$201B | 5.9x | 10.5x | |
$177B | 2.8x | 7.3x | |
$155B | 5.4x | 12.6x | |
$142B | 2.8x | 9.5x | |
$137B | 2.9x | 12.1x | |
$110B | 9.7x | 40.4x | |
$97.5B | 2.3x | 6.6x | |
$87.5B | 5.7x | 16.9x | |
$79.4B | 8.5x | 19.8x | |
$79.3B | 9.7x | 19.6x | |
$73.8B | 2.3x | 9.0x | |
$64.3B | 2.7x | 9.4x | |
$63.9B | 1.2x | 5.8x | |
$52.7B | 6.3x | 22.0x | |
$46.2B | 11.4x | 44.8x | |
$45.5B | 3.5x | 17.0x | |
$44.9B | 7.2x | 25.3x | |
$35.7B | 2.1x | 7.2x | |
$26.0B | 9.2x | 30.7x | |
$24.5B | 2.2x | 11.0x | |
$23.8B | 1.7x | 5.4x | |
$23.7B | 1.5x | 6.4x | |
$23.5B | 2.5x | 7.3x | |
$22.0B | 2.2x | 6.4x | |
$21.6B | 1.6x | 8.5x | |
$19.6B | 6.8x | 7.3x | |
$16.8B | 2.0x | 8.2x | |
$16.5B | 9.4x | 25.2x | |
$15.8B | 26.3x | 52.8x | |
$14.3B | 5.1x | 13.9x | |
$12.8B | 9.3x | 28.6x | |
$12.7B | 117.4x | 280.5x | |
$12.7B | 3.9x | 15.2x | |
$12.6B | 8.5x | 33.8x | |
$12.3B | 8.6x | 280.9x | |
$12.1B | 2.1x | 15.4x | |
$12.0B | 3.1x | 11.6x | |
$11.7B | 4.2x | 11.6x | |
$11.7B | 4.7x | 18.7x | |
$10.9B | 1.9x | 11.3x | |
$10.9B | 1.7x | 5.6x | |
$10.6B | 3.9x | 16.6x | |
$10.4B | 1.7x | 13.7x | |
$10.3B | 3.7x | 12.7x | |
$10.0B | 2.5x | 10.1x | |
$9.7B | 2.9x | 8.3x | |
$9.7B | 3.2x | 7.8x | |
$9.5B | 25.0x | -761.5x | |
$9.4B | 2.3x | 9.9x | |
$9.3B | 3.0x | 7.3x | |
$9.3B | 2.3x | 6.5x | |
$9.2B | 5.2x | 15.6x | |
$8.5B | 31.8x | -249.7x | |
$8.0B | 2.1x | 10.1x | |
$7.5B | 0.2x | 3.5x | |
$7.5B | 6.8x | 10.6x | |
$7.4B | 2.2x | 8.6x | |
$7.3B | 1.3x | 11.1x | |
$7.2B | 9.5x | 35.4x | |
$7.1B | n/a | n/a | |
$7.0B | 4.5x | 22.9x | |
$6.8B | 1.7x | 9.0x | |
$6.6B | 2.0x | 8.5x | |
$6.6B | 14.9x | 20.3x | |
$6.3B | 3.4x | 16.4x | |
$6.2B | n/a | n/a | |
$6.2B | 13.9x | 44.3x | |
$5.7B | 3.7x | 57.1x | |
$5.7B | 4.8x | 13.3x | |
$5.7B | 2.6x | 9.6x | |
$5.7B | 8.8x | 30.1x | |
$5.6B | 3.8x | 8.8x | |
$5.3B | 2.8x | 11.1x | |
$5.0B | n/a | n/a | |
$5.0B | 5.7x | 13.0x | |
$4.8B | 11.9x | 38.5x | |
$4.8B | 1.7x | 7.5x | |
$4.8B | 1.9x | 5.2x | |
$4.7B | 10.3x | 24.3x | |
$4.7B | 3.0x | 16.5x | |
$4.6B | 1.9x | 8.3x | |
$4.6B | 8.2x | 28.9x | |
$4.5B | 1.4x | 5.8x | |
$4.5B | 10.0x | 26.6x | |
$4.4B | 5.8x | 20.1x | |
$4.3B | 15.8x | -34.6x | |
$4.3B | 8.6x | 33.8x | |
$4.2B | 10.3x | 32.7x | |
$4.2B | 2.8x | 10.6x | |
$4.2B | 3.0x | 11.0x | |
$4.1B | 2.0x | 13.3x | |
$4.1B | 13.2x | -38.3x | |
$4.0B | 5.0x | 28.1x | |
$3.8B | 41.6x | -1904.4x | |
$3.7B | 5.9x | 14.6x | |
$3.7B | n/a | n/a | |
$3.7B | n/a | n/a | |
$3.6B | n/a | n/a | |
$3.5B | 4.3x | 21.0x | |
$3.2B | 8.6x | 26.0x | |
$3.2B | 2.0x | 10.0x | |
$3.1B | 3.7x | 14.0x | |
$3.1B | 4.4x | 16.1x | |
$3.1B | 2.3x | 8.5x | |
$3.0B | 2.7x | 12.8x | |
$2.9B | n/a | n/a | |
$2.8B | n/a | n/a | |
$2.8B | 7.5x | 46.2x | |
$2.7B | n/a | n/a | |
$2.7B | 46.8x | -241.3x | |
$2.7B | 2.3x | 11.4x | |
$2.6B | 4.2x | 15.9x | |
$2.5B | 869.3x | -9.9x | |
$2.4B | 3.2x | 17.8x | |
$2.3B | n/a | n/a | |
$2.3B | 20.7x | -31.3x | |
$2.3B | 5.9x | 13.7x | |
$2.3B | 3.5x | 8.3x | |
$2.2B | 7.7x | 15.3x | |
$2.2B | 3.0x | 16.3x | |
$2.1B | 5.4x | 15.2x | |
$2.1B | 12.7x | -32.7x | |
$2.0B | 14.3x | 34.6x | |
$2.0B | 290.8x | n/a | |
$1.9B | 5.0x | 14.0x | |
$1.8B | 2.6x | 10.1x | |
$1.7B | 3.5x | -1095.1x | |
$1.7B | 4.0x | 20.0x | |
$1.7B | 11.6x | -19.9x | |
$1.6B | 2.2x | 5.8x | |
$1.6B | 2.3x | 3.8x | |
$1.5B | 7.5x | 40.9x | |
$1.5B | 6.3x | -15.3x | |
$1.5B | 13.8x | -30.4x | |
$1.5B | 2.3x | -63.1x | |
$1.5B | 26.6x | -16.9x | |
$1.5B | 3.9x | 15.4x | |
$1.5B | 17.4x | 43.9x | |
$1.5B | 1.3x | 5.2x | |
$1.5B | 5.5x | -18.0x | |
$1.5B | 0.7x | 4.0x | |
$1.5B | n/a | n/a | |
$1.4B | 2.5x | 10.2x | |
$1.4B | 4.9x | -10.0x | |
$1.4B | 1.4x | 6.0x | |
$1.3B | 2.1x | 7.8x | |
$1.3B | 9.4x | n/a | |
$1.3B | 90.1x | n/a | |
$1.3B | 0.6x | n/a | |
$1.2B | 3.4x | n/a | |
$1.2B | 3.1x | 13.2x | |
$1.2B | 33.4x | n/a | |
$1.2B | 5.0x | 21.2x | |
$1.1B | 1.7x | -7.6x | |
$1.1B | 2.4x | 16.3x | |
$1.1B | n/a | n/a | |
$1.1B | 21.4x | n/a | |
$1.1B | n/a | n/a | |
$1.0B | 4.5x | 68.9x | |
$1.0B | 9.6x | 14.7x | |
$985M | 5.4x | 20.9x | |
$959M | n/a | -6.1x | |
$941M | 8.9x | 267.0x | |
$932M | n/a | n/a | |
$921M | 9.2x | 17.3x | |
$905M | 3.6x | 6.5x | |
$905M | 2.6x | -53.9x | |
$874M | n/a | n/a | |
$870M | n/a | n/a | |
$867M | 0.9x | 5.2x | |
$844M | 3.4x | n/a | |
$831M | n/a | -2.3x | |
$828M | 4.0x | 153.7x | |
$823M | 4.6x | 22.2x | |
$797M | 2.7x | 21.1x | |
$797M | 931.9x | -8.2x | |
$784M | n/a | -3.7x | |
$765M | 1.2x | 6.4x | |
$752M | 6.9x | 32.0x | |
$742M | 8.3x | -5.2x | |
$734M | n/a | n/a | |
$731M | 4.2x | n/a | |
$723M | n/a | n/a | |
$722M | 2.3x | -538.5x | |
$704M | n/a | n/a | |
$701M | n/a | n/a | |
$678M | n/a | -3.5x | |
$667M | 31.2x | -250.3x | |
$667M | n/a | n/a | |
$661M | 5.8x | 21.9x | |
$644M | n/a | -3.8x | |
$641M | 2.5x | 11.0x | |
$639M | 6.5x | 27.8x | |
$638M | 223.9x | -9.3x | |
$593M | 1.9x | 5.9x | |
$581M | 198029.1x | -5.0x | |
$579M | n/a | n/a | |
$549M | n/a | n/a | |
$547M | 90.7x | n/a | |
$546M | 1.2x | 5.8x | |
$545M | 5.5x | 15.9x | |
$544M | 6.3x | -4.3x | |
$543M | n/a | -6.2x | |
$536M | n/a | n/a | |
$522M | 8.0x | 31.5x | |
$515M | 24.0x | 157.7x | |
$507M | n/a | -2.3x | |
$500M | 3045.1x | -3.2x | |
$499M | n/a | -2.2x | |
$491M | n/a | n/a | |
$488M | 453.4x | -24.0x | |
$459M | 1.4x | 6.2x | |
$456M | 82.8x | -2.0x | |
$453M | 1.2x | 9.4x | |
$450M | n/a | n/a | |
$442M | 61.6x | -12.9x | |
$440M | n/a | n/a | |
$419M | 3.7x | -55.2x | |
$419M | 47.1x | -11.1x | |
$414M | 5.8x | -22.3x | |
$410M | 30.3x | -3.7x | |
$399M | 6.3x | -1.2x | |
$366M | n/a | -2.6x | |
$362M | n/a | -4.3x | |
$358M | n/a | -3.2x | |
$356M | 1.1x | 10.1x | |
$354M | 2.2x | 9.9x | |
$335M | 0.9x | 7.4x | |
$328M | 1.9x | 8.6x | |
$322M | 1.2x | 8.1x | |
$319M | 8.2x | -25.0x | |
$319M | 30.7x | n/a | |
$317M | n/a | n/a | |
$316M | 30.5x | -1.8x | |
$312M | 59.8x | n/a | |
$307M | 22172.6x | -2.9x | |
$306M | 4.0x | 15.3x | |
$303M | n/a | -2.4x | |
$293M | n/a | n/a | |
$292M | 3.0x | -1.4x | |
$290M | 7.2x | 32.9x | |
$282M | n/a | n/a | |
$279M | n/a | n/a | |
$278M | 2.1x | 4.3x | |
$268M | n/a | n/a | |
$264M | 2.6x | -10.1x | |
$262M | 1.5x | -2.6x | |
$261M | n/a | n/a | |
$258M | 4.7x | n/a | |
$254M | n/a | n/a | |
$244M | n/a | n/a | |
$240M | 3.5x | n/a | |
$237M | 10.2x | -4.2x | |
$229M | n/a | n/a | |
$226M | 30.8x | -0.8x | |
$225M | 3.6x | 6.8x | |
$221M | 4.6x | 17.6x | |
$210M | 70.8x | -1.0x | |
$208M | n/a | n/a | |
$202M | 38.0x | -4.5x | |
$199M | 11.7x | 22.7x | |
$194M | 3.2x | -7.8x | |
$193M | 1.6x | 2.9x | |
$191M | n/a | n/a | |
$187M | 1.5x | 14.7x | |
$187M | 1.3x | -0.9x | |
$185M | n/a | -2.2x | |
$179M | n/a | -1.6x | |
$178M | n/a | n/a | |
$176M | 1.9x | -2.7x | |
$176M | 28.1x | -3.7x | |
$175M | 63.9x | n/a | |
$174M | 21.5x | -6.8x | |
$171M | 1.3x | -1.6x | |
$165M | 45.6x | -4.4x | |
$163M | n/a | n/a | |
$157M | n/a | -0.9x | |
$155M | 1.8x | -4.2x | |
$149M | 1.3x | -0.8x | |
$147M | 2.7x | 6.6x | |
$147M | 7.3x | -0.9x | |
$144M | n/a | n/a | |
$134M | n/a | n/a | |
$132M | 5.3x | -3.0x | |
$131M | n/a | n/a | |
$128M | 2.2x | -1.7x | |
$116M | 5.8x | 17.5x | |
$114M | 1084.8x | -7.7x | |
$112M | 1.1x | -1.1x | |
$108M | n/a | n/a | |
$108M | 1.9x | 11.5x | |
$107M | 16.0x | -0.6x | |
$99.1M | n/a | n/a | |
$97.5M | 9.3x | -3.4x | |
$97.1M | 1.6x | n/a | |
$95.5M | n/a | n/a | |
$93.9M | 3.7x | -0.7x | |
$93.3M | n/a | n/a | |
$90.0M | 1.5x | 18.9x | |
$88.8M | 3.2x | -1.6x | |
$84.7M | n/a | -0.6x | |
$83.0M | 15.7x | -2.6x | |
$82.7M | 6.1x | n/a | |
$82.4M | n/a | n/a | |
$73.3M | 35.5x | -0.7x | |
$72.9M | n/a | n/a | |
$72.9M | n/a | -2.2x | |
$72.8M | 2.0x | n/a | |
$70.5M | n/a | -2.6x | |
$70.0M | 0.3x | -0.2x | |
$66.6M | n/a | n/a | |
$66.6M | 14.2x | n/a | |
$63.7M | n/a | n/a | |
$62.8M | 16.0x | -62.9x | |
$62.4M | 18.6x | -7.8x | |
$61.6M | 0.8x | 7.2x | |
$59.0M | n/a | n/a | |
$58.1M | n/a | -0.6x | |
$55.1M | 2.1x | -0.6x | |
$53.3M | n/a | -0.5x | |
$49.1M | n/a | n/a | |
$48.2M | 9.2x | -4.8x | |
$46.9M | 1.3x | -105.7x | |
$43.3M | 67.8x | -5.7x | |
$41.2M | 8.1x | -1.6x | |
$39.9M | n/a | n/a | |
$39.8M | 5.7x | -1.6x | |
$39.7M | n/a | -1.9x | |
$39.5M | 10.6x | -12.3x | |
$38.0M | n/a | n/a | |
$37.7M | n/a | n/a | |
$36.1M | n/a | n/a | |
$35.5M | n/a | -6.3x | |
$34.6M | 1.4x | 8.7x | |
$33.8M | n/a | n/a | |
$33.1M | n/a | -0.3x | |
$33.0M | n/a | n/a | |
$32.7M | n/a | -10.1x | |
$31.2M | n/a | -2.9x | |
$30.7M | n/a | n/a | |
$30.5M | n/a | n/a | |
$29.5M | n/a | -17.8x | |
$29.2M | n/a | n/a | |
$28.9M | n/a | n/a | |
$28.9M | 7.6x | n/a | |
$28.7M | 2.1x | -14.7x | |
$27.1M | 6.5x | -1.6x | |
$27.0M | n/a | n/a | |
$26.3M | n/a | n/a | |
$25.7M | n/a | n/a | |
$24.5M | 28.9x | -40.0x | |
$24.1M | n/a | n/a | |
$23.6M | n/a | n/a | |
$23.5M | 14.2x | -38.6x | |
$22.6M | n/a | n/a | |
$21.7M | n/a | n/a | |
$21.7M | n/a | n/a | |
$19.6M | 5.7x | n/a | |
$19.5M | 4.7x | -2.1x | |
$19.3M | 16.8x | -12.9x | |
$19.0M | n/a | n/a | |
$17.8M | n/a | n/a | |
$17.7M | n/a | n/a | |
$17.6M | 14.1x | -8.0x | |
$17.3M | n/a | n/a | |
$17.0M | n/a | n/a | |
$16.8M | 59.1x | -9.4x | |
$16.8M | 15.8x | -9.9x | |
$16.7M | n/a | n/a | |
$16.3M | n/a | n/a | |
$15.9M | 3.0x | -1.0x | |
$15.3M | n/a | n/a | |
$15.3M | 35.5x | -1.4x | |
$14.4M | 2.3x | -0.8x | |
$13.6M | n/a | n/a | |
$13.5M | 2.2x | 6.7x | |
$12.9M | n/a | n/a | |
$12.6M | n/a | n/a | |
$12.0M | n/a | n/a | |
$11.7M | n/a | n/a | |
$11.6M | 2.1x | -4.1x | |
$11.4M | n/a | n/a | |
$11.2M | n/a | n/a | |
$11.0M | n/a | n/a | |
$10.8M | n/a | n/a | |
$8.9M | n/a | n/a | |
$8.8M | n/a | n/a | |
$8.7M | 6.1x | -18.4x | |
$8.4M | 3.8x | -0.4x | |
$8.4M | n/a | -3.9x | |
$8.3M | n/a | n/a | |
$7.9M | n/a | -2.6x | |
$7.8M | 2.6x | -2.2x | |
$7.3M | n/a | n/a | |
$7.2M | 7.4x | -0.6x | |
$7.2M | n/a | n/a | |
$6.9M | 0.2x | -0.0x | |
$6.3M | n/a | n/a | |
$6.0M | n/a | n/a | |
$5.7M | 1.4x | -3.0x | |
$5.3M | n/a | n/a | |
$5.3M | n/a | n/a | |
$5.2M | n/a | -2.5x | |
$4.9M | n/a | -1.4x | |
$4.8M | 3.7x | -1.1x | |
$4.7M | 4.6x | n/a | |
$4.7M | n/a | -1.2x | |
$4.6M | n/a | n/a | |
$4.6M | n/a | n/a | |
$4.6M | 22.2x | -1.4x | |
$4.4M | n/a | n/a | |
$4.3M | n/a | n/a | |
$4.1M | n/a | n/a | |
$4.0M | 31.4x | -4.0x | |
$4.0M | n/a | n/a | |
$3.9M | n/a | n/a | |
$3.8M | n/a | n/a | |
$3.8M | n/a | -0.0x | |
$3.8M | n/a | n/a | |
$3.7M | n/a | n/a | |
$3.7M | n/a | n/a | |
$3.6M | n/a | n/a | |
$3.2M | n/a | n/a | |
$3.1M | n/a | n/a | |
$3.0M | 2.5x | -0.0x | |
$2.7M | n/a | n/a | |
$2.5M | n/a | n/a | |
$2.1M | n/a | -16.9x | |
$1.9M | 3.7x | -0.8x | |
$1.6M | n/a | n/a | |
$1.3M | 0.1x | -0.1x | |
$1.2M | n/a | n/a | |
$1.1M | n/a | n/a | |
$0.9M | n/a | n/a | |
$0.7M | 0.8x | -0.2x | |
$0.6M | 0.1x | -0.4x | |
$0.5M | n/a | n/a | |
$0.5M | 0.4x | -0.0x | |
$0.3M | n/a | n/a | |
$12K | n/a | n/a | |
-$0.7M | n/a | n/a | |
-$0.7M | n/a | n/a | |
-$1.5M | n/a | n/a | |
-$1.9M | -2.2x | n/a | |
-$2.5M | n/a | n/a | |
-$3.7M | -0.1x | 0.0x | |
-$6.2M | -203.8x | 0.6x | |
-$6.2M | n/a | n/a | |
-$6.7M | n/a | n/a | |
-$7.2M | -1.9x | 0.1x | |
-$11.8M | -21.6x | n/a | |
-$15.1M | n/a | n/a | |
-$22.2M | n/a | n/a | |
-$22.6M | n/a | n/a | |
-$23.6M | n/a | n/a | |
-$28.2M | -4.1x | 0.2x | |
-$28.9M | n/a | 0.2x | |
-$32.0M | -0.2x | 0.4x | |
-$33.5M | n/a | n/a | |
-$42.8M | -4.8x | n/a | |
-$49.3M | -6.2x | 1.1x | |
-$62.3M | n/a | 0.6x | |
-$92.3M | -37.5x | 1.5x | |
-$93.8M | n/a | 0.6x | |
-$126M | -77.9x | 0.6x | |
-$135M | -12.5x | 0.4x | |
-$155M | -1.7x | n/a | |
-$161M | -235.6x | 0.8x | |
-$168M | -301.8x | 2.4x | |
-$172M | -2.7x | 1.0x | |
-$1.8B | -5.6x | 10.0x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Biopharmaceuticals